4basebio Full Year 2022 Earnings: Revenues Disappoint

4basebio (LON:4BB) Full Year 2022 Results

Key Financial Results

• Net loss: UK£5.15m (loss widened by 59% from FY 2021).
• UK£0.42 loss per share (further deteriorated from UK£0.26 loss in FY 2021).

All figures shown in the chart above are for the trailing 12 month (TTM) period

4basebio Revenues Disappoint

Revenue missed analyst estimates by 11%. Earnings per share (EPS) was mostly in line with analyst estimates.

The company's shares are down 7.9% from a week ago.

Risk Analysis

It is worth noting though that we have found 4 warning signs for 4basebio (3 are a bit unpleasant!) that you need to take into consideration.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.